Use of probiotics in prevention and treatment of patients with Clostridium difficile infection

Best Practice and Research: Clinical Gastroenterology

Volumn 30, Issue 1, 2016, Pages 111-118

  Ollech, Jacob E ^a   Shen, Nicole T ^c   Crawford, Carl V ^c   Ringel, Yehuda ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clostridium difficile; Intestinal microbiome; Probiotics; Pseudomembranous colitis

Indexed keywords

ANTIINFECTIVE AGENT; PROBIOTIC AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COLON FLORA; DRUG USE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; INFECTION PREVENTION; INTESTINE EPITHELIUM; INTESTINE FLORA; NONHUMAN; RECURRENT DISEASE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL TRACT; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; PROBIOTICS;

EID: 84958206125     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2016.01.002     Document Type: Review

References (44)

1. D.A. Leffler, and J.T. Lamont Clostridium difficile infection N Engl J Med 373 3 2015 287 288 10.1056/NEJMc1506004
2. F.C. Lessa, Y. Mu, W.M. Bamberg, Z.G. Beldavs, G.K. Dumyati, J.R. Dunn, and et al. Burden of Clostridium difficile infection in the United States N Engl J Med 372 9 2015 825 834 10.1056/NEJMoa1408913
3. J.L. Kuntz, and P.M. Polgreen The importance of considering different healthcare settings when estimating the burden of Clostridium difficile Clin Infect Dis 60 6 2015 831 836 10.1093/cid/ciu955
4. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 173(22):2039-2046. doi:10.1001/jamainternmed.2013.9763.
5. F.C. Lessa, C.V. Gould, and L.C. McDonald Current status of Clostridium difficile infection epidemiology Clin Infect Dis 55 Suppl. 2 2012 S65 S70 10.1093/cid/cis319
6. M. Kamboj, P. Khosa, A. Kaltsas, N.E. Babady, C. Son, and K.A. Sepkowitz Relapse versus reinfection: surveillance of Clostridium difficile infection Clin Infect Dis 53 10 2011 1003 1006 10.1093/cid/cir643
7. L.V. McFarland, G.W. Elmer, and C.M. Surawicz Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease Am J Gastroenterol 97 7 2002 1769 1775 10.1111/j.1572-0241.2002.05839.x
8. J.Y. Chang, D.A. Antonopoulos, A. Kalra, A. Tonelli, W.T. Khalife, T.M. Schmidt, and et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea J Infect Dis 197 3 2008 435 438 10.1086/525047
9. T.J. Louie, M.A. Miller, K.M. Mullane, K. Weiss, A. Lentnek, and Y. Golan Fidaxomicin versus vancomycin for Clostridium difficile infection N Engl J Med 364 5 2011 422 431 10.1056/NEJMoa0910812
10. E. van Nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, E.G. Zoetendal, W.M. de Vos, and et al. Duodenal infusion of donor feces for recurrent Clostridium difficile N Engl J Med 368 5 2013 407 415 10.1056/NEJMoa1205037
11. I. Youngster, J. Sauk, C. Pindar, R.G. Wilson, J.L. Kaplan, M.B. Smith, and et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study Clin Infect Dis 58 11 2014 1515 1522 10.1093/cid/ciu135
12. B.C. Johnston, S.S. Ma, J.Z. Goldenberg, K. Thorlund, P.O. Vandvik, M. Loeb, and et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis Ann Intern Med 157 12 2012 878 888 10.7326/0003-4819-157-12-201212180-00563
13. C.W. Van Niel, C. Feudtner, M.M. Garrison, and D.A. Christakis Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis Pediatrics 109 4 2002 678 684 http://www.ncbi.nlm.nih.gov/pubmed/11927715 (accessed 30.11.15)
14. J.Z. Goldenberg, S.S. Ma, J.D. Saxton, M.R. Martzen, P.O. Vandvik, K. Thorlund, and et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Cochrane Database Syst Rev 5 2013 10.1002/14651858.CD006095.pub3 CD006095
15. Y. Ringel, E.M. Quigley, and H.C. Lin Using probiotics in gastrointestinal disorders Am J Gastroenterol Suppl 1 1 2012 34 40 10.1038/ajgsup.2012.7
16. S. Oh, S.H. Kim, and R.W. Worobo Characterization and purification of a bacteriocin produced by a potential probiotic culture, Lactobacillus acidophilus 30SC J Dairy Sci 83 12 2000 2747 2752 10.3168/jds.S0022-0302(00)75169-1
17. S.C. Corr, Y. Li, C.U. Riedel, P.W. O'Toole, C. Hill, and C.G.M. Gahan Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118 Proc Natl Acad Sci U S A 104 18 2007 7617 7621 10.1073/pnas.0700440104
18. C.M. Galdeano, and G. Perdigon The probiotic Bacterium lactobacillus casei induces activation of the gut mucosal immune system through innate immunity Clin Vaccine Immunol 13 2 2006 219 226 10.1128/CVI.13.2.219-226.2006
19. J. Auclair, M. Frappier, and M. Millette Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium dif Clin Infect Dis 60 Suppl. 2 2015 S135 S143 10.1093/cid/civ179
20. M.C. Rea, E. Clayton, P.M. O'Connor, F. Shanahan, B. Kiely, R.P. Ross, and et al. Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains J Med Microbiol 56 Pt 7 2007 940 946 10.1099/jmm.0.47085-0
21. I. Castagliuolo, M.F. Riegler, L. Valenick, J.T. LaMont, and C. Pothoulakis Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa Infect Immun 67 1 1999 302 307 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=96311&tool=pmcentrez&rendertype=abstract (accessed 30.11.15)
22. M.A. Kalliomäki, and W.A. Walker Physiologic and pathologic interactions of bacteria with gastrointestinal epithelium Gastroenterol Clin North Am 34 3 2005 383 399 10.1016/j.gtc.2005.05.007 vii
23. A. Tasteyre, M.-C. Barc, T. Karjalainen, P. Bourlioux, and A. Collignon Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii Microb Pathog 32 5 2002 219 225 10.1006/mpat.2002.0495
24. P. Banerjee, G.J. Merkel, and A.K. Bhunia Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells Gut Pathog 1 1 2009 8 10.1186/1757-4749-1-8
25. D. Rachmilewitz, K. Katakura, F. Karmeli, T. Hayashi, C. Reinus, and B. Rudensky Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis Gastroenterology 126 2 2004 520 528 http://www.ncbi.nlm.nih.gov/pubmed/14762789 (accessed 30.11.15)
26. H.S. Gill, K.J. Rutherfurd, and M.L. Cross Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes J Clin Immunol 21 4 2001 264 271 http://www.ncbi.nlm.nih.gov/pubmed/11506196 (accessed 30.11.15)
27. A. Qamar, S. Aboudola, M. Warny, P. Michetti, C. Pothoulakis, J.T. LaMont, and et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice Infect Immun 69 4 2001 2762 2765 10.1128/IAI.69.4.2762-2765.2001
28. K. Orrhage, S. Sjöstedt, and C.E. Nord Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil J Antimicrob Chemother 46 4 2000 603 612 http://www.ncbi.nlm.nih.gov/pubmed/11020259 (accessed 30.11.15)
29. P. Naaber, and M. Mikelsaar Interactions between Lactobacilli and antibiotic-associated diarrhea Adv Appl Microbiol 54 2004 231 260 10.1016/S0065-2164(04)54009-1
30. G.W. Elmer, and L.V. McFarland Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters Antimicrob Agents Chemother 31 1 1987 129 131 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174670&tool=pmcentrez&rendertype=abstract (accessed 30.11.15)
31. S.J. Allen, K. Wareham, D. Wang, C. Bradley, H. Hutchings, W. Harris, and et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial Lancet (London, England) 382 9900 2013 1249 1257 10.1016/S0140-6736(13)61218-0
32. M.R. Thomas, S.C. Litin, D.R. Osmon, A.P. Corr, A.L. Weaver, and C.M. Lohse Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial Mayo Clin Proc 76 9 2001 883 889 10.4065/76.9.883
33. L.V. McFarland, C.M. Surawicz, R.N. Greenberg, G.W. Elmer, K.A. Moyer, S.A. Melcher, and et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo Am J Gastroenterol 90 3 1995 439 448 http://www.ncbi.nlm.nih.gov/pubmed/7872284 (accessed 30.11.15)
34. C.M. Surawicz, G.W. Elmer, P. Speelman, L.V. McFarland, J. Chinn, and G. van Belle Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study Gastroenterology 96 4 1989 981 988 http://www.ncbi.nlm.nih.gov/pubmed/2494098 (accessed 30.11.15)
35. M. Beausoleil, N. Fortier, S. Guénette, A. L'ecuyer, M. Savoie, M. Franco, and et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial Can J Gastroenterol 21 11 2007 732 736 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2658588&tool=pmcentrez&rendertype=abstract (accessed 25.11.15)
36. X.W. Gao, M. Mubasher, C.Y. Fang, C. Reifer, and L.E. Miller Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients Am J Gastroenterol 105 7 2010 1636 1641 10.1038/ajg.2010.11
37. J.G. Lan, S.M. Cruickshank, J.C. Singh, M. Farrar, J.P. Lodge, P.J. Felsburg, and et al. Different cytokine response of primary colonic epithelial cells to commensal bacteria World J Gastroenterol 11 22 2005 3375 3384 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4315991&tool=pmcentrez&rendertype=abstract (accessed 30.11.15)
38. S. Hempel, S.J. Newberry, A.R. Maher, Z. Wang, J.N. Miles, and R. Shanman Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis JAMA 307 18 2012 1959 1969 10.1001/jama.2012.3507
39. L.V. McFarland Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease Am J Gastroenterol 101 4 2006 812 822 10.1111/j.1572-0241.2006.00465.x
40. S.H. Cohen, D.N. Gerding, S. Johnson, C.P. Kelly, V.G. Loo, L.C. McDonald, and et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) Infect Control Hosp Epidemiol 31 5 2010 431 455 10.1086/651706
41. C.M. Surawicz, L.J. Brandt, D.G. Binion, A.N. Ananthakrishnan, S.R. Curry, P.H. Gilligan, and et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections Am J Gastroenterol 108 4 2013 478 498 10.1038/ajg.2013.4 quiz 499
42. C.T. Evans, and S. Johnson Prevention of Clostridium difficile infection with probiotics Clin Infect Dis 60 Suppl. 2 2015 S122 S128 10.1093/cid/civ138
43. S. Doron, and D.R. Snydman Risk and safety of probiotics Clin Infect Dis 60 Suppl. 2 2015 S129 S134 10.1093/cid/civ085
44. T. Didari, S. Solki, S. Mozaffari, S. Nikfar, and M. Abdollahi A systematic review of the safety of probiotics Expert Opin Drug Saf 13 2 2014 227 239 10.1517/14740338.2014.872627